Publicacións en colaboración con investigadores/as de AstraZeneca (United Kingdom) (5)

2022

  1. Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy

    Diabetes Therapy, Vol. 13, Núm. 7, pp. 1281-1298

  2. Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

    Diabetes Therapy, Vol. 13, Núm. 5, pp. 873-888

2021

  1. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial

    European Heart Journal, Vol. 42, Núm. 13, pp. 1216-1227

2019

  1. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180

2017

  1. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 377, Núm. 13, pp. 1228-1239